other material
confidence high
sentiment negative
materiality 0.65
Galera converts 76.5K Series B preferred into 76.5M common shares; warrants exercised
Galera Therapeutics, Inc.
- Converted 76,479.175 Series B Preferred shares into 76,479,164 common shares on April 7, 2026.
- After conversion, 42,839.11 Series B Preferred shares remain outstanding.
- Ikarian Capital affiliates exercised pre-funded warrants for 8,488,229 common shares at $0.001/share on April 8, 2026.
- Remaining pre-funded warrants to purchase 14,552,811 common shares outstanding.